Liquisolid Technology: A Strategy for Dissolution Enhancement of BCS Class II Drugs

The current investigation was used to find out the role of liquisolid technology to improve the rate of dissolution of mosapride citrate (BCS class II). Different Liquisolid formulations were prepared by using polyethylene glycol 400 as a non-volatile solvent, Avicel PH 102 as a carrier and Aerosil 200 as a coating material. Liquisolid tablets ware characterized by FTIR, DSC, XRD and in-vitro dissolution studies. Characterisation studies indicated that interactions were absent between drug and carrier, reduction in the crystallinity and that will support further the enhancement of solubility and rate of dissolution. The optimised formulation showed a significant increase in dissolution i.e., 99.69±1.47% in 30 min compared to directly compressible tablets (31.48±1.58%). DE (dissolution efficiency) was increased from 15.16 % for direct compression tablet to 70.5% for mosapride citrate liquisolid tablets. MDT (mean dissolution time) of mosapride citrate was significantly reduced from 57.27 min for direct compression tablet to 7.58 min for optimized formulation indicating faster release of drug. Liquisolid tablets could be a promising method for of improvement of solubility, enhancement of dissolution and bioavailability of mosapride citrate.